By Fineline Cube 
China-based Zhejiang Jolly Pharmaceutical Co., Ltd. (SHE: 300181) announced an investment of RMB 20 million (USD 2.7 million) in Lingyi Biotech Co., Ltd., a domestic gene therapy specialist. Additionally, Jolly Pharma has secured priority rights to obtain the distribution rights or sales agency rights for Lingyi Bio’s LY-N001, a drug for Parkinson’s disease (PD), in mainland China.
Partnership and Investment Details
The investment underscores Jolly Pharma’s commitment to advancing gene therapy solutions. The two companies first partnered in November of the previous year, focusing on equity cooperation, research and development (R&D), and sales collaboration. This latest move further solidifies their strategic alliance, positioning both firms to leverage their respective strengths in the development and commercialization of innovative therapies.-Fineline Info & Tech